Skip to main content
. 2017 Feb 28;8(12):19843–19854. doi: 10.18632/oncotarget.15773

Figure 1.

Figure 1

(A) Western blot of lysates of BCPAP cells treated with 0.1 μM dabrafenib with or without 1 μM lapatinib for indicated times. Lapatinib blocked the dabrafenib-induced HER3 and AKT phosphorylation and the pERK1/2 rebound. (B) BCPAP cells were treated with 2.5 μM selumetib with or without 1 μM lapatinib and collected at 0, 1, 8, and 48 h post-treatment. Lysates were Western blotted for HER3 and ERK.